Works matching IS 15268209 AND DT 2017 AND VI 17 AND IP 1


Results: 17
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Epirubicin With Cyclophosphamide Followed by Docetaxel With Trastuzumab and Bevacizumab as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group, FB-5.

    Published in:
    2017
    By:
    • Smith II, John W.;
    • Buyse, Marc E.;
    • Rastogi, Priya;
    • Geyer Jr., Charles E.;
    • Jacobs, Samuel A.;
    • Patocskai, Erica J.;
    • Robidoux, André;
    • Conlin, Alison K.;
    • Ansari, Bilal;
    • Keogh, George P.;
    • Stella, Philip J.;
    • Gross, Howard M.;
    • Lord, Raymond S.;
    • Polikoff, Jonathan A.;
    • Mauquoi, Celine;
    • Mamounas, Eleftherios P.;
    • Swain, Sandra M.;
    • Wolmark, Norman;
    • Smith, John W 2nd;
    • Geyer, Charles E Jr
    Publication type:
    journal article
    12
    13
    14
    15
    16
    17